1. Scrip
  2. >>Business

Deal Watch: More Predictions 2017 Will Be A Banner Year For Deal-Making

 
• By Joseph Haas and Ying Huang

PwC anticipates a streamlining of the FDA approval process could address asset scarcity. AbbVie begins 2017 with three modest-sized deals, while PharmAthene and Altimmune join forces in a reverse-merger.

DealWatch_1200x675

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions that occurred between Jan. 9-24. Deal Watch is supported by deal intelligence from Strategic Transactions.

Despite a scarcity of assets and biotech valuations that many would-be acquirers or licensors consider too high, the consultants at PwC predicts that the likelihood of regulatory and tax reform under the new Trump administration could lead to

More from Deals

More from Business

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.